Bristol Myers Squibb joins the race to build a large pharma AI supercomputer

Another drugmaker says it is building one of pharma's largest NVIDIA-based AI systems to speed drug discovery.

Bristol Myers Squibb says it is building what it claims is pharma's largest NVIDIA-based AI supercomputer, dedicated to drug discovery. It joins other drugmakers making similar claims, which itself signals that the industry now sees large-scale computing as core infrastructure for finding new medicines.

Drug discovery is slow and expensive, with most candidates failing along the way. Applying more computing power to model molecules and predict outcomes is meant to narrow the search earlier, which could shorten timelines and reduce the cost of getting a working drug to patients.

The payoff for health depends on whether faster computation actually produces medicines that work — a machine built is not a drug approved. This is an early, capacity-building move. We are working only from the metadata; the source was unreachable, so the system's specifications and BMS's plans sit with the original reporting.

Source: STAT